Switching from the originator infliximab to biosimilar CT-P13 did not change the quality of life and clinical efficacy for IBD patients in stable remission in daily clinical practice (interim analysis)

M. J. Pierik, A. E. van der Meulen-de Jong, J. P. J. Bloemsaat-Minekus, Y. J. B. van Megen, G. Dijkstra

OnderzoeksoutputAcademic

Originele taal-2English
Pagina's (van-tot)S339-S340
Aantal pagina's2
TijdschriftJournal of Crohn's and Colitis
Volume12
StatusPublished - feb.-2018

Citeer dit